Akeso, Inc. (FRA:4RY)

Market Cap	12.90B +68.3%
Revenue (ttm)	372.16M +43.9%
Net Income	-135.53M
EPS	-0.15
Shares Out	n/a
PE Ratio	n/a
Forward PE	107.27
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	210
Open	13.70
Previous Close	13.50
Day's Range	13.70 - 13.90
52-Week Range	7.40 - 19.30
Beta	n/a
RSI	65.48
Earnings Date	Mar 26, 2026

About Akeso

Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, liver cancer, and esophageal cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell carcinoma, breast cancer, colorectal cancer, and pancreatic cancer. It is also developing AK117, a CD47 monoclonal antibody to treat my...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 3,761
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4RY

Financial Performance

In 2025, Akeso's revenue was 3.06 billion, an increase of 43.90% compared to the previous year's 2.12 billion. Losses were -1.11 billion, 116.3% more than in 2024.

Financial numbers in CNY